SCHEMBL16629639

SCHEMBL16629639

CC1(C)c2cc3c(cc2-c2cc4c5ccccc5n(-c5cccc6ccc7cccnc7c56)c4cc21)c1ccccc1n3-c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
ATM Q13315 1/20 0.35
MAPT P10636 5/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP3A4 P08684 2/20 0.32
GAA P10253 2/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
TNKS O95271 1/20 0.31
SLC22A12 Q96S37 1/20 0.31
CCR1 P32246 4/20 0.31
CCR8 P51685 4/20 0.31
CCR5 P51681 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
HTT P42858 2/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629645 0.95 MAPT (0.36) KDM4EL3MBTL1MAPTNPSR1CYP3A4
SCHEMBL16629640 0.94 KDM4E (0.31) KDM4EMAPTNPSR1
SCHEMBL16629615 0.92 METAP2 (0.30)
SCHEMBL17946128 0.92 METAP2 (0.30)
SCHEMBL16629683 0.91 MAPT (0.34) KDM4EL3MBTL1MAPTNPSR1CYP3A4
SCHEMBL17945949 0.87 MAPT (0.36) KDM4EL3MBTL1MAPTNPSR1CYP3A4
SCHEMBL16629630 0.87 KDM4E (0.42) KDM4EL3MBTL1ATMMAPTNPSR1
SCHEMBL16629628 0.87 KDM4E (0.42) KDM4EL3MBTL1ATMMAPTNPSR1
SCHEMBL16629611 0.86 FABP1 (0.32) KDM4EMAPTCYP3A4CCR1CCR8
SCHEMBL16629618 0.86 KDM4E (0.33) KDM4EMAPTNPSR1CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices MERCK PATENT GMBH (DE) 2019-09-10 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
WO-2015049022-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES KCNQ1, KCNH1, KCNQ2 KDM4E 1939/4885L3MBTL1 2372/4885ATM 1799/4885
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices KCNQ1, KCNH1, KCNQ2 KDM4E 1939/4885L3MBTL1 2372/4885ATM 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.